Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy: A Prospective Longitudinal Cohort.
Primary Objectives:
1. To quantify RT-related changes in circulating biomarkers of CV stress, inflammation and vascular dysfunction, and to define the associations between RT dose-volume measures and biomarkers.
2. To quantify RT-related changes in imaging-derived measures of CV function and perfusion, and to define the associations between RT dose-volume measures and CV function and perfusion.
3. To determine the prognostic value of biologic, imaging, and RT dose-volume measures as indicators of adverse CV outcomes, by defining the associations between early changes in these measures and CV outcomes.
Secondary Objectives:
1. To determine the associations between changes in CV biomarkers and QOL and activity measures.
2. To determine the associations between changes in measures of cardiac function and perfusion and QOL and activity measures
3. To determine the associates between changes in RT dose volume measures and QOL and activity measures.
- Rutgers Cancer Institute of New Jersey
Inclusion Criteria
- At least 18 years of age
- Histologically confirmed or clinically diagnosed non-small cell lung cancer where the
plan is for definitive treatment that includes radiation
- Able to give written informed consent
Exclusion Criteria
- Pregnant or breast-feeding
- Prior treatment with anthracyclines
- Radiation treatment not expected to involve any heart exposure as determined by
treating provider
- ECOG performance status greater than 2
- Vulnerable patients, including pregnant women and prisoners
- Contraindication to rest/vasodilator stress PET/CT, including: asthma with ongoing
wheezing at time of enrollment; known Mobitz Type II AV block, 3rd degree AV block, or
sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmHg;
known hypersensitivity to Regadenoson and adenosine; profound sinus bradycardia (heart
rate less than 40bpm).
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.